The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Omniscan     2-[bis[2-(carboxylatomethyl...

Synonyms: Omniscan (TN), AC1L1TUZ, CTK8E8484, AKOS015967052, DB00225, ...
This record was replaced with 60755.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid


High impact information on 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid

  • Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging [1].
  • MATERIALS AND METHODS: LLC-PK1 cells were incubated with iomeprol, gadopentetate dimeglumine, gadobenate dimeglumine, gadoterate meglumine, gadodiamide, and corresponding mannitol solutions for 24 hours at 37 degrees C in two experimental settings: measurements with equally attenuating solutions and measurements with equimolar solutions [6].
  • CONCLUSION: Noninferiority of gadodiamide versus gadopentetate was verified based on the primary end point, which was accuracy for detection of the main stenosis with enhanced 3D MR angiography compared with DSA [7].
  • T1 values increased significantly (P < .05) to 720 msec +/- 7 for 0.05 mmol/mL gadodiamide and 445 msec +/- 6 for 0.10 mmol/mL gadodiamide 30 minutes after injection but remained significantly lower than those of remote myocardium (879 msec +/- 8) [8].
  • CONCLUSION: Gadoversetamide and gadodiamide caused a transient artifact in measurement of serum calcium levels with an OCP assay but not with an arzenazo III technique or inductively coupled plasma mass spectrometry [9].

Chemical compound and disease context of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid


Biological context of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid


Anatomical context of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid

  • It is concluded that gadodiamide injection is safe and effective for MR imaging of the head and spine in patients with suspected abnormalities of the central nervous system [19].
  • Gadodiamide-enhanced angiograms appeared to be better than CO2-enhanced angiograms for help in identifying renal artery occlusions, visualizing renal vessels incompletely filled with CO2, and determining the progress of intervention [2].
  • Echo-planar MR imaging of normal and ischemic myocardium with gadodiamide injection [20].
  • Skull base tumors: gadodiamide injection--enhanced MR imaging--drop-out effect in the early enhancement pattern of paragangliomas versus different tumors [21].
  • Rapid echo-planar (EP) magnetic resonance (MR) imaging was used to monitor the first pass of a bolus of gadodiamide injection in the hearts of normal rats and rats subjected to left coronary artery occlusion [20].

Associations of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid with other chemical compounds


Gene context of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid

  • PURPOSE: To evaluate the time-signal intensity (SI) curves generated from intravenous (IV) gadodiamide-enhanced dynamic magnetic resonance (MR) urographic scans for identifying vesicoureteral reflux (VUR) during bladder filling [25].
  • Dynamic contrast-enhanced MR images of 12 patients with acute pneumonia and 13 patients with exacerbation of COPD were acquired in both the coronal and transaxial planes (an inversion recovery prepared gradient-echo sequence using 0.05 mmol/kg gadodiamide/injection) [26].
  • Gadodiamide (Omniscan, Amersham Health, Cork, Ireland) and gadoversetamide (OptiMARK, Mallinckrodt, St. Louis, MO) did produce noticeable-and therefore potentially misleading-effects at these concentrations [27].
  • METHODS: Nineteen patients with Crohn's disease (CD), 8 with ulcerative colitis (UC), and 5 healthy controls (HC) were examined using MRI (0.1 T) before and after intravenously administered gadodiamide and glucagon [28].
  • For MR-angiography, a Flash 3D sequence was utilized following injection of 5 mL diluted gadodiamide (Omniscan; Amersham Buchler, Braunschweig, Germany) via the arterial access [29].

Analytical, diagnostic and therapeutic context of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid

  • In normal brain, dose-dependent decreases in signal intensity were observed after intravenous injection of 0.15-0.50 mmol/kg dysprosium-diethylenetriaminepentaacetic acid bismethylamide or gadodiamide injection [30].
  • Seventy-three patients (34 male, 39 female; age range, 17-84 years) who were clinically suspected of having RAS underwent contrast material-enhanced (gadodiamide) saturation-recovery turbo fast low-angle shot imaging for measurement of renal perfusion and high-spatial-resolution MR angiography for RAS detection and grading [31].
  • Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine [19].
  • Results of MR angiography with 0.1 mmol/kg and 0.3 mmol/kg doses of gadodiamide were compared with those of digital subtraction angiography (DSA) and according to dose [5].
  • The fDVs of gadodiamide injection and (99m)Tc-DTPA were measured and compared by using inversion-recovery echo-planar imaging and autoradiographic phosphor imaging, respectively [10].


  1. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. Marckmann, P., Skov, L., Rossen, K., Dupont, A., Damholt, M.B., Heaf, J.G., Thomsen, H.S. J. Am. Soc. Nephrol. (2006) [Pubmed]
  2. Renal insufficiency: usefulness of gadodiamide-enhanced renal angiography to supplement CO2-enhanced renal angiography for diagnosis and percutaneous treatment. Spinosa, D.J., Matsumoto, A.H., Angle, J.F., Hagspiel, K.D., McGraw, J.K., Ayers, C. Radiology. (1999) [Pubmed]
  3. Pulmonary embolism: detection with MR perfusion imaging of lung--a feasibility study. Amundsen, T., Kvaerness, J., Jones, R.A., Waage, A., Bjermer, L., Nilsen, G., Haraldseth, O. Radiology. (1997) [Pubmed]
  4. Gadodiamide administration causes spurious hypocalcemia. Prince, M.R., Erel, H.E., Lent, R.W., Blumenfeld, J., Kent, K.C., Bush, H.L., Wang, Y. Radiology. (2003) [Pubmed]
  5. Safety and effectiveness of single- versus triple-dose gadodiamide injection- enhanced MR angiography of the abdomen: a phase III double-blind multicenter study. Thurnher, S.A., Capelastegui, A., Del Olmo, F.H., Dondelinger, R.F., Gervás, C., Jassoy, A.G., Keto, P., Loewe, C., Ludman, C.N., Marti-Bonmati, L., Meusel, M., da Cruz, J.P., Pruvo, J.P., Sanjuan, V.M., Vogl, T. Radiology. (2001) [Pubmed]
  6. Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study. Heinrich, M.C., Kuhlmann, M.K., Kohlbacher, S., Scheer, M., Grgic, A., Heckmann, M.B., Uder, M. Radiology (2007) [Pubmed]
  7. Abdominal and iliac arterial stenoses: comparative double-blinded randomized study of diagnostic accuracy of 3D MR angiography with gadodiamide or gadopentetate dimeglumine. Schaefer, P.J., Boudghene, F.P., Brambs, H.J., Bret-Zurita, M., Caniego, J.L., Coulden, R.A., Gehl, H.B., Hammerstingl, R., Huber, A., Mendez, R.J., Nonent, M., Oestmann, J.W., Pueyo, J.C., Thurnher, S., Weishaupt, D., Jahnke, T. Radiology. (2006) [Pubmed]
  8. MR-guided percutaneous intramyocardial injection with an MR-compatible catheter: feasibility and changes in T1 values after injection of extracellular contrast medium in pigs. Krombach, G.A., Pfeffer, J.G., Kinzel, S., Katoh, M., Günther, R.W., Buecker, A. Radiology. (2005) [Pubmed]
  9. Measurement of serum calcium concentration after administration of gadoversetamide in dogs. Wible, J.H., Hynes, M.R. Radiology. (2004) [Pubmed]
  10. Reperfused rat myocardium subjected to various durations of ischemia: estimation of the distribution volume of contrast material with echo-planar MR imaging. Arheden, H., Saeed, M., Higgins, C.B., Gao, D.W., Ursell, P.C., Bremerich, J., Wyttenbach, R., Dae, M.W., Wendland, M.F. Radiology. (2000) [Pubmed]
  11. Renal artery stenting using gadodiamide arteriography in patients with baseline renal insufficiency. Harb, T.S., Laird, J.R., Dieter, R.S., Reddy, B.K., Whitman, D., Babrowicz, J.C., Satler, L.F. J. Endovasc. Ther. (2004) [Pubmed]
  12. Local tissue toxicity in response to extravascular extravasation of magnetic resonance contrast media. Runge, V.M., Dickey, K.M., Williams, N.M., Peng, X. Investigative radiology. (2002) [Pubmed]
  13. Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency. Spinosa, D.J., Angle, J.F., Hagspiel, K.D., Kern, J.A., Hartwell, G.D., Matsumoto, A.H. Journal of vascular and interventional radiology : JVIR. (2000) [Pubmed]
  14. Transendocardial delivery of extracellular myocardial markers by using combination X-ray/MR fluoroscopic guidance: feasibility study in dogs. Saeed, M., Lee, R., Martin, A., Weber, O., Krombach, G.A., Schalla, S., Lee, M., Saloner, D., Higgins, C.B. Radiology. (2004) [Pubmed]
  15. In vivo dynamics and distribution of intracerebroventricularly administered gadodiamide, visualized by magnetic resonance imaging. Bui, J.D., Nammari, D.R., Buckley, D.L., Inglis, B.A., Silver, X.S., Mareci, T.H., Phillips, M.I. Neuroscience (1999) [Pubmed]
  16. MRI measurement of cell volume fraction in the perfused rat hippocampal slice. Buckley, D.L., Bui, J.D., Phillips, M.I., Blackband, S.J. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. (1999) [Pubmed]
  17. Effects of three different doses of a bolus injection of gadodiamide: assessment of regional cerebral blood volume maps in a blinded reader study. Bruening, R., Berchtenbreiter, C., Holzknecht, N., Essig, M., Wu, R.H., Simmons, A., Heuck, A., Maschek, A., Meusel, M., Williams, S.C., Cox, T., Knopp, M.V., Reiser, M. AJNR. American journal of neuroradiology. (2000) [Pubmed]
  18. Gadolinium inhibits thymidine incorporation and induces apoptosis in chondrocytes. Greisberg, J.K., Wolf, J.M., Wyman, J., Zou, L., Terek, R.M. J. Orthop. Res. (2001) [Pubmed]
  19. Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Sze, G., Brant-Zawadzki, M., Haughton, V.M., Maravilla, K.R., McNamara, M.T., Kumar, A.J., Aisen, A.M., Dreisbach, J.N., Bradley, W.G., Weinreb, J.C. Radiology. (1991) [Pubmed]
  20. Echo-planar MR imaging of normal and ischemic myocardium with gadodiamide injection. Wendland, M.F., Saeed, M., Masui, T., Derugin, N., Moseley, M.E., Higgins, C.B. Radiology. (1993) [Pubmed]
  21. Skull base tumors: gadodiamide injection--enhanced MR imaging--drop-out effect in the early enhancement pattern of paragangliomas versus different tumors. Vogl, T.J., Mack, M.G., Juergens, M., Bergman, C., Grevers, G., Jacobsen, T.F., Lissner, J., Felix, R. Radiology. (1993) [Pubmed]
  22. Gadolinium as a CT contrast agent: assessment in a porcine model. Gierada, D.S., Bae, K.T. Radiology. (1999) [Pubmed]
  23. Magnetic resonance imaging of the cochlea, spiral ganglia and eighth nerve of the guinea pig. Counter, S.A., Bjelke, B., Klason, T., Chen, Z., Borg, E. Neuroreport (1999) [Pubmed]
  24. MR ventriculography for the study of CSF flow. Joseph, V.B., Raghuram, L., Korah, I.P., Chacko, A.G. AJNR. American journal of neuroradiology. (2003) [Pubmed]
  25. Intravenous contrast-enhanced dynamic MR urography: diagnosis of vesicoureteral reflux during bladder filling with time-signal intensity curves. Kocaoglu, M., Bulakbasi, N., Ilica, A.T., Gok, F., Tayfun, C., Somuncu, I. Journal of magnetic resonance imaging : JMRI. (2006) [Pubmed]
  26. Perfusion magnetic resonance imaging of the lung: characterization of pneumonia and chronic obstructive pulmonary disease. A feasibility study. Amundsen, T., Torheim, G., Waage, A., Bjermer, L., Steen, P.A., Haraldseth, O. Journal of magnetic resonance imaging : JMRI. (2000) [Pubmed]
  27. Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing. Löwe, A., Balzer, T., Hirt, U. Investigative radiology. (2005) [Pubmed]
  28. Active Crohn's disease and ulcerative colitis evaluated by low-field magnetic resonance imaging. Madsen, S.M., Thomsen, H.S., Munkholm, P., Dorph, S., Schlichting, P. Scand. J. Gastroenterol. (1998) [Pubmed]
  29. Feasibility of MR-guided angioplasty of femoral artery stenoses using real-time imaging and intraarterial contrast-enhanced MR angiography. Paetzel, C., Zorger, N., Bachthaler, M., Völk, M., Seitz, J., Herold, T., Feuerbach, S., Lenhart, M., Nitz, W.R. RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin. (2004) [Pubmed]
  30. Echo-planar perfusion-sensitive MR imaging of acute cerebral ischemia. Kucharczyk, J., Vexler, Z.S., Roberts, T.P., Asgari, H.S., Mintorovitch, J., Derugin, N., Watson, A.D., Moseley, M.E. Radiology. (1993) [Pubmed]
  31. Renal artery stenosis: functional assessment with dynamic MR perfusion measurements--feasibility study. Michaely, H.J., Schoenberg, S.O., Oesingmann, N., Ittrich, C., Buhlig, C., Friedrich, D., Struwe, A., Rieger, J., Reininger, C., Samtleben, W., Weiss, M., Reiser, M.F. Radiology. (2006) [Pubmed]
WikiGenes - Universities